Q-omics provides the consensus-scored CCDC107 profile across patient tissues and cancer cell-line models. CCDC107 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CCDC107 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, CCDC107 RNA expression shows 18,101 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, KIRC, and ACC as cancer lineages where CCDC107 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC107 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC107 survival associations across molecular data types. CCDC107 RNA expression shows survival associations in the most cancer types (24), followed by mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC107 RNA expression–survival associations across cancer types. High CCDC107 expression shows unfavorable associations in UVM, ACC, LUSC, CESC, LGG and ESCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CCDC107 RNA expression.
This table summarizes CCDC107 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for CCDC107. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC107 shows lower tumor expression in BLCA, LUSC and COAD and higher tumor expression in KIRC, LIHC and HNSC. The KIRC box plot shows higher CCDC107 RNA expression in tumor versus normal tissue (log2 FC = +0.719, t-test p < 0.001).
This table shows molecular features associated with CCDC107 in patient tissues and cancer cell lines. In patient samples, CCDC107 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC107 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and CNS.
